Drug Pricing: Innovation, Investment, and the Public Good

The US biotech and life sciences industry has a long and proud history of driving medical innovations that have improved healthcare outcomes across a wide range of diseases and the overall quality of life for people worldwide.

For too long, however, the industry’s narrative has been dominated and defined by partisans with a specific agenda who do not always provide the broader public with the context needed to be fully informed on key issues.